Company intelligence / Profile preview
Xigen
Epalinges / Lausanne area, Vaud / VD, Switzerlandxigen.co.uk ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Xigen’s lead compound, brimapitide (XG‑102), is a highly selective peptide-based inhibitor of c-Jun N-terminal kinase. It has completed a first-in-human Phase 1 study demonstrating safety and tolerability via intravenous administration. The company is advancing additional programs in inflammatory and neurodegenerative diseases using its proprietary cell-permeable peptide platform.
- Therapeutic areas
- OncologyNeurologyCardiovascularImmunology
- Modalities
- PeptidesPeptide-based therapyCell-penetrating peptide therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Auris Medical AG – licensing and development partnership for ear disorder therapies using neuroprotective peptides from Xigen's platform. Auris Medical obtained worldwide exclusive rights to use these peptides in ear disorders such as hearing loss or tinnitus.
Beyond the preview
Go deeper on Xigen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xigen.